Mahadevia Ankit
Spero Therapeutics, Inc. · Director
Mahadevia Ankit is listed in filings as Director at Spero Therapeutics, Inc.. This profile follows SEC Form 4 activity through Sep 3, 2025, including sale activity. Recent filings connect the profile to Spero Therapeutics, Inc. (SPRO). The current snapshot covers public activity from Aug 29, 2024 to Sep 3, 2025. Reported amounts are shown as $12.9K to $10.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $43k55.3k shares | SellFeb 5, 2025 | $0.78 | $2.90 | |
| $11k14k shares | SellFeb 5, 2025 | $0.78 | $2.90 | |
| $8.0k5.9k shares | SellAug 27, 2024 | $1.35 | $2.90 |